Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1991 1
1997 1
2000 1
2001 3
2003 3
2004 5
2006 4
2007 3
2008 9
2009 5
2010 8
2011 1
2012 7
2013 8
2014 8
2015 12
2016 16
2017 21
2018 24
2019 22
2020 24
2021 27
2022 28
2023 28
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Results by year

Filters applied: . Clear all
Page 1
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Abou-El-Enein M, et al. Among authors: till bg. Blood Cancer Discov. 2021 Sep;2(5):408-422. doi: 10.1158/2643-3230.BCD-21-0084. Epub 2021 Aug 3. Blood Cancer Discov. 2021. PMID: 34568831 Free PMC article. Review.
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till B, Raghunathan VM, Alig S, Alizadeh AA, Gulhane A, Chen DL, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas J, Gopal AK. Lynch RC, et al. Among authors: till b. Blood. 2023 May 25;141(21):2576-2586. doi: 10.1182/blood.2022019254. Blood. 2023. PMID: 36913694 Clinical Trial.
Functional Genomics for Plant Breeding.
Maghuly F, Myśków B, Till BJ. Maghuly F, et al. Among authors: till bj. Int J Mol Sci. 2021 Nov 1;22(21):11854. doi: 10.3390/ijms222111854. Int J Mol Sci. 2021. PMID: 34769285 Free PMC article.
TILLING: The Next Generation.
Till BJ, Datta S, Jankowicz-Cieslak J. Till BJ, et al. Adv Biochem Eng Biotechnol. 2018;164:139-160. doi: 10.1007/10_2017_54. Adv Biochem Eng Biotechnol. 2018. PMID: 29516116 Review.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. Cowan AJ, et al. Among authors: till bg. Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2. Lancet Oncol. 2023. PMID: 37414012 Clinical Trial.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday RD, Chapuis AG, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Gauthier J, et al. Among authors: till bg. Blood. 2021 Jan 21;137(3):323-335. doi: 10.1182/blood.2020006770. Blood. 2021. PMID: 32967009 Free PMC article. Clinical Trial.
Robotic Minimally Invasive Esophagectomy.
Till BM, Grenda TR, Okusanya OT, Evans Iii NR. Till BM, et al. Thorac Surg Clin. 2023 Feb;33(1):81-88. doi: 10.1016/j.thorsurg.2022.09.004. Thorac Surg Clin. 2023. PMID: 36372536 Review.
ChatGPT, Artificial Intelligence, and Suicide Prevention.
Arendt F, Till B, Voracek M, Kirchner S, Sonneck G, Naderer B, Pürcher P, Niederkrotenthaler T. Arendt F, et al. Among authors: till b. Crisis. 2023 Sep;44(5):367-370. doi: 10.1027/0227-5910/a000915. Crisis. 2023. PMID: 37737578 Free article. No abstract available.
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Hirayama AV, et al. Among authors: till bg. Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19. Blood. 2019. PMID: 30782611 Free PMC article. Clinical Trial.
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: till bg. Blood Adv. 2023 Nov 28;7(22):6990-7005. doi: 10.1182/bloodadvances.2023011399. Blood Adv. 2023. PMID: 37774014 Free PMC article. Clinical Trial.
236 results